AusBiotech

A new Cell and Gene Catalyst is being established to capitalise on the opportunities that the burgeoning cell and gene sector can deliver to the Australian economy and society, with co-leads AusBiotech and Medicines Australia seeking expressions of interest from industry partners interested in contributing to and supporting the initiative.

Clinical-stage drug development company Dimerix (ASX:DXB) has announced that the Indian regulator has formally recommended the approval of the study of DMX-200 in patients with COVID-19.

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that the US patent office has allowed claims relating to the use of a combination of its Veyonda and radiotherapy.

Cell therapy company Cynata Therapeutics (ASX:CYP) has announced that a scientific paper describing the use of its Cymerus mesenchymal stem cells in a model of myocardial infarction has been published in the peer-reviewed journal Cytotherapy.

EnGeneIC says it has developed a unique nano cellular technology that in pre-clinical animal studies has been shown to stimulate a broad and powerful anti-COVID-19 immune response.

AusBiotech, Cell Therapies, Research Strategies Australia and MTPConnect have made a joint submission to the parliamentary inquiry into the opportunity for Australia's manufacturing industry to harness the potential of emerging cell and gene therapies, or regenerative medicines.

Clinical stage immuno-oncology company Imugene (ASX:IMU) has announced it has received a notice of grant from the Japanese Patent Office for its application to protect its HER-Vaxx immunotherapy.

Rhythm Biosciences (ASX:RHY) has announced the appointment of a new chair with the resignation of incumbent Shane Tanner.

Experts have released research that says drug repurposing is no quick fix for developing new treatments for COVID-19 with inherent dangers and pitfalls in translating drugs to treat the virus.

Monash University has announced it will establish a Victorian Health Innovation Centre, including a flagship cardiovascular disease-focused research accelerator, HeartLabs, as well as a new focal point for clinical trials.

AusBiotech is seeking member feedback as it responds to the Department of Health’s Review of the National Medicines Policy.

Clinical-stage biopharmaceutical company Bionomics (ASX:BNO) has announced it will proceed with evaluating its lead clinical compound, BNC210, for the treatment of acute Social Anxiety Disorder.